FIVE PRIME THERAPEUTICS INC's ticker is FPRX and the CUSIP is 33830X104. A total of 124 filers reported holding FIVE PRIME THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.52 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $28,000 | -54.8% | 4,651 | 0.0% | 0.00% | – |
| Q1 2019 | $62,000 | +47.6% | 4,651 | 0.0% | 0.00% | – |
| Q4 2018 | $42,000 | -35.4% | 4,651 | 0.0% | 0.00% | – |
| Q3 2018 | $65,000 | -11.0% | 4,651 | 0.0% | 0.00% | – |
| Q2 2018 | $73,000 | -8.8% | 4,651 | 0.0% | 0.00% | – |
| Q1 2018 | $80,000 | -21.6% | 4,651 | 0.0% | 0.00% | – |
| Q4 2017 | $102,000 | +12.1% | 4,651 | +98.3% | 0.00% | – |
| Q3 2017 | $91,000 | +28.2% | 2,346 | 0.0% | 0.00% | – |
| Q2 2017 | $71,000 | -16.5% | 2,346 | 0.0% | 0.00% | – |
| Q1 2017 | $85,000 | -28.0% | 2,346 | 0.0% | 0.00% | – |
| Q4 2016 | $118,000 | -52.0% | 2,346 | -50.0% | 0.00% | – |
| Q3 2016 | $246,000 | +153.6% | 4,692 | +100.0% | 0.00% | – |
| Q2 2016 | $97,000 | +2.1% | 2,346 | 0.0% | 0.00% | – |
| Q1 2016 | $95,000 | -2.1% | 2,346 | 0.0% | 0.00% | – |
| Q4 2015 | $97,000 | – | 2,346 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eventide Asset Management | 601,000 | $24,587,000 | 1.39% |
| HealthCor Management, L.P. | 1,010,930 | $41,357,000 | 1.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 86,500 | $3,535,000 | 1.38% |
| PURA VIDA INVESTMENTS, LLC | 75,000 | $3,068,000 | 0.90% |
| BB BIOTECH AG | 777,500 | $31,808,000 | 0.88% |
| AWM Investment Company, Inc. | 100,000 | $4,091,000 | 0.71% |
| Granite Point Capital Management, L.P. | 50,000 | $2,046,000 | 0.43% |
| Rock Springs Capital Management LP | 217,700 | $8,906,000 | 0.41% |
| Crestline Management, LP | 50,919 | $2,083,000 | 0.29% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,432,700 | $99,522,000 | 0.24% |